Tagworks Pharmaceuticals

Tagworks Pharmaceuticals is a clinical-stage biotech pioneering a Nobel Prize-inspired Click-to-Release platform to revolutionize targeted cancer therapies. Its core technology uses a bioorthogonal chemical reaction triggered by an administered molecule to precisely release drug payloads at the tumor site, aiming to overcome key limitations of ADCs and radiopharmaceuticals. The company has two clinical-stage assets: TGW101, an ADC targeting the non-internalizing antigen TAG72 in solid tumors (Phase 1), and TGW211, a HER2-directed radioimmunoconjugate (Phase 0/1). Backed by a seasoned team and leading life science investors, Tagworks is positioned to expand the targetable landscape in oncology with its innovative prodrug activation approach.

Click-to-Release platform utilizing in vivo bioorthogonal click chemistry for controlled activation of prodrugs (e.g., ADCs) in tumors or deactivation of radiopharmaceuticals off-target.

Tagworks competes in the ADC space against large pharma (e.g., AstraZeneca, Daiichi Sankyo) and biotechs developing next-generation linker/payload technologies. Its unique angle is targeting non-internalizing antigens via external activation. In radiopharmaceuticals, it competes with companies like Novartis and Point Biopharma, differentiating itself with a chemical clearance mechanism rather than a biological one.